Cite this answer
Retatrutide vs Semaglutide: Triple Agonist vs Market Leader: quick citable summary
This PeptaHub comparison summarizes Retatrutide and Semaglutide side by side, covering category, legal status, primary route, half-life, mechanism, and editorial verdict for writers and AI answer engines.
PeptaHub. “Retatrutide vs Semaglutide: Triple Agonist vs Market Leader.” peptahub.com, 2026. https://peptahub.com/compare/retatrutide-vs-semaglutide. Licensed CC BY 4.0.
License: Creative Commons Attribution 4.0 International. Link back to https://peptahub.com/compare/retatrutide-vs-semaglutide.
Head-to-head comparison
| Property | Retatrutide | Semaglutide |
|---|---|---|
| Category | Weight Loss | Weight Loss |
| Legal Status | Research Only | Prescription |
| Primary Route | subcutaneous | subcutaneous |
| Half-life | ~6 days | ~7 days |
| Mol. Weight | 4,894.58 Da | 4,113.58 Da |
| Side Effects | Nausea (most common, dose-dependent), Vomiting, Diarrhea | Nausea (39%), Vomiting, Diarrhea |
Key differences
- Receptor targets: Retatrutide activates GLP-1, GIP, and glucagon receptors simultaneously; semaglutide activates GLP-1 receptors only.
- Weight loss efficacy: Phase 3 TRIUMPH-1 topline data reported retatrutide (12 mg) achieved 28.3% mean weight loss at 80 weeks, with about 45% reaching at least 30%; semaglutide (2.4 mg) achieved 15–17% at 68 weeks in STEP trials.
- Energy expenditure: Retatrutide's glucagon component increases resting energy expenditure; semaglutide's weight loss is driven primarily by appetite suppression and reduced caloric intake.
- Approval status: Semaglutide is FDA-approved with multiple indications and years of real-world data; retatrutide has Phase 3 topline data but remains investigational and not FDA-approved.
- Manufacturer: Retatrutide is developed by Eli Lilly; semaglutide by Novo Nordisk.
- Liver fat: Retatrutide Phase II showed substantial liver fat reduction, potentially relevant for MASH; semaglutide also reduces liver fat but less aggressively.
- Safety profile: Semaglutide has extensive Phase III and post-market safety data; retatrutide has Phase II safety data with Phase III ongoing.
The verdict
Retatrutide's Phase 3 TRIUMPH-1 topline data is remarkable — 28.3% mean weight loss at 80 weeks, with about 45% of participants reaching at least 30% weight loss. The triple-agonist mechanism addresses obesity from multiple angles. However, semaglutide is FDA-approved, commercially available, and has years of safety data. Retatrutide remains investigational and not FDA-approved, so semaglutide is the proven current treatment while retatrutide is a pipeline contender awaiting full regulatory review.
Frequently asked questions
If regulators approve retatrutide and the full Phase 3 package supports the TRIUMPH-1 topline efficacy, it could become a preferred weight loss medication for some patients. However, semaglutide will likely remain a standard treatment option, similar to how semaglutide coexists with liraglutide. Market competition will depend on approval, labeling, pricing, access, and safety profiles.
Phase 3 TRIUMPH-1 topline data reported 28.3% mean weight loss with retatrutide at 80 weeks, with about 45% of participants reaching at least 30%, versus 15–17% with semaglutide at 68 weeks in STEP trials. This is a cross-trial comparison, not a head-to-head result, and retatrutide remains investigational and not FDA-approved.
Available Phase 2 and Phase 3 topline data report GI side effects similar to other incretin therapies, but full peer-reviewed Phase 3 safety data and long-term outcomes are still limited. Semaglutide has substantially more safety evidence from large Phase III trials and years of post-market surveillance.
No, they are competitors. Retatrutide is developed by Eli Lilly (which also makes tirzepatide), while semaglutide is developed by Novo Nordisk. This represents a major pipeline rivalry between the two leading obesity pharmaceutical companies.
Beyond GLP-1 (appetite suppression), retatrutide adds GIP (enhanced insulin sensitivity, fat metabolism) and glucagon (increased energy expenditure, hepatic fat oxidation). This three-pronged approach may explain the superior weight loss: reducing intake, improving metabolism, and increasing expenditure simultaneously.